Volume 24, Issue 6
June 2022
Cover image
Cover image
Figure 1 from the article by Xue, He, and Zhang et al. “Origins of biallelic inactivation of NF2 in neurofibromatosis type 2” beginning on p. 903.
ISSN 1522-8517
EISSN 1523-5866
Issue navigation
Volume 24, Issue 6, June 2022
Editorial
Bioethical implications of current state practices of molecular diagnostics in neuropathology
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 853–854, https://doi.org/10.1093/neuonc/noac058
Review
Liquid biopsy in gliomas: A RANO review and proposals for clinical applications
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 855–871, https://doi.org/10.1093/neuonc/noac004
Basic and Translational Investigations
Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 872–885, https://doi.org/10.1093/neuonc/noab241
Editorial
CD55, a potential immunotherapeutic target for MYCN-amplified neuroblastoma
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 886–887, https://doi.org/10.1093/neuonc/noac020
Basic and Translational Investigations
ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 888–900, https://doi.org/10.1093/neuonc/noab292
Editorial
Loss of ATRX suppresses anti-tumor immunity
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 901–902, https://doi.org/10.1093/neuonc/noac059
Basic and Translational Investigations
Origins of biallelic inactivation of NF2 in neurofibromatosis type 2
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 903–913, https://doi.org/10.1093/neuonc/noab287
Neuronal exposure induces neurotransmitter signaling and synaptic mediators in tumors early in brain metastasis
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 914–924, https://doi.org/10.1093/neuonc/noab290
Transcription factor GTF2B regulates AIP protein expression in growth hormone-secreting pituitary adenomas and influences tumor phenotypes
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 925–935, https://doi.org/10.1093/neuonc/noab291
Clinical Investigations
SIOP Ependymoma I: Final results, long-term follow-up, and molecular analysis of the trial cohort—A BIOMECA Consortium Study
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 936–948, https://doi.org/10.1093/neuonc/noac012
Editorial
Pediatric ependymoma: New perspectives on older trials
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 949–950, https://doi.org/10.1093/neuonc/noac060
Clinical Investigations
Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 951–963, https://doi.org/10.1093/neuonc/noab271
Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 964–973, https://doi.org/10.1093/neuonc/noab240
Pediatric Neuro-Oncology
Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children’s Oncology Group study
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 974–983, https://doi.org/10.1093/neuonc/noab270
Editorial
Chemotherapy plus focal radiation therapy for localized intracranial germinoma: How little is enough?
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 984–985, https://doi.org/10.1093/neuonc/noac047
Pediatric Neuro-Oncology
Radiomic signatures of posterior fossa ependymoma: Molecular subgroups and risk profiles
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 986–994, https://doi.org/10.1093/neuonc/noab272
Editorial
Radiomics—A new age of presurgical assessment to improve outcomes in pediatric neuro-oncology
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 995–996, https://doi.org/10.1093/neuonc/noac046
Pediatric Neuro-Oncology
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 997–1007, https://doi.org/10.1093/neuonc/noab274
Editorial
TRK inhibition for pediatric and adult central nervous system tumors: Early promise and future questions
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 1008–1009, https://doi.org/10.1093/neuonc/noac048
Pediatric Neuro-Oncology
Decade-long disease, secondary malignancy, and brainstem injury outcomes in pediatric and young adult medulloblastoma patients treated with proton radiotherapy
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 1010–1019, https://doi.org/10.1093/neuonc/noab257
Neuroimaging
Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 1020–1028, https://doi.org/10.1093/neuonc/noab276
Letters to the Editor
Two clinically distinct cases of infant hemispheric glioma carrying ZCCHC8:ROS1 fusion and responding to entrectinib
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 1029–1031, https://doi.org/10.1093/neuonc/noac026
Standardizing reporting of brain and central nervous system tumors in the United Kingdom
Neuro-Oncology, Volume 24, Issue 6, June 2022, Pages 1032–1033, https://doi.org/10.1093/neuonc/noac027
Society News
Forthcoming Meetings
Neuro-Oncology, Volume 24, Issue 6, June 2022, Page 1034, https://doi.org/10.1093/neuonc/noac129
